Drug intelligence / Profile preview

hydromorphone + dexmedetomidine

Development stage: Unknown
Lead developer: Orion
Modality: Small Molecules
Administration: Intramuscular

Overview

Hydromorphone + dexmedetomidine is a drug combination used for premedication in anesthesia protocols. This combination provides sedation, analgesia, and facilitates subsequent treatments or interventions. Hydromorphone is an opioid that blocks pain signals in the brain, while dexmedetomidine is a highly selective alpha-2 agonist that provides sedation. When combined, they produce neuroleptanalgesia with synergistic effects that allow for lower doses of each drug to be used while providing effective sedation and analgesia.

Other names: HD treatment

Targets

ADRA2C (α2C)ADRA2B (α2B)ADRA2A (α2A)ADRA1A (α1A)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on hydromorphone + dexmedetomidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydromorphone + dexmedetomidine.

Explore the full profile